Top

BMC Women's Health

Published in:

Open Access 01-12-2024 | Human Papillomavirus | Research

Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18

Authors: Min Xu, Miao-Chun Lin, Zhao-Hui Li

Published in: BMC Women's Health | Issue 1/2024

Abstract

Background

Human papillomavirus (HPV) infection is an important factor leading to cervical cell abnormalities. 90% of cervical cancers are closely associated with persistent infection of high-risk HPV, with the highest correlation with HPV16 and 18. Currently available vaccines and antivirals have limited effectiveness and coverage. Guanylate binding protein 1 (GBP1) was induced by interferon gamma and involved in many important cellular processes such as clearance of various microbial pathogens. However, whether GBP1 can inhibit human papillomavirus infection is unclear.

Results

In this study, we found that GBP1 can effectively degrade HPV18 E6, possibly through its GTPase activity or other pathways, and E6 protein degrades GBP1 through the ubiquitin-proteasome pathway to achieve immune escape.

Conclusion

Therefore, GBP1 is an effector of IFN-γ anti-HPV activity. Our findings provided new insights into the treatment of HPV 18 infections.

Peng Q, Wang L, Zuo L, et al. HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor. Cancer Gene Ther. 2024;31:9–17. https://doi.org/10.1038/s41417-023-00682-3CrossRefPubMed

Rahangdale L, Mungo C, O’Connor S, et al. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115. https://doi.org/10.1136/bmj-2022-070115CrossRefPubMed

Perkins RB, Wentzensen N, Guido RS, et al. Cerv Cancer Screening: Rev JAMA. 2023;330:547–58. https://doi.org/10.1001/jama.2023.13174

Silva LLD, Teles AM, Santos JMO, et al. Malignancy Associated with low-risk HPV6 and HPV11: a systematic review and implications for Cancer Prevention. Cancers (Basel). 2023;15. https://doi.org/10.3390/cancers15164068

Luria L, Cardoza-Favarato G, et al. Human Papillomavirus, StatPearls, 2024.

Schneider WM, Chevillotte M, DRice C. M Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–45. https://doi.org/10.1146/annurev-immunol-032713-120231

Wang Y, Fan X, Song Y, et al. SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA. Cell Mol Immunol. 2021;18:1032–44. https://doi.org/10.1038/s41423-020-0431-xCrossRefPubMed

Li Z, Ning S, Su X, et al. Enterovirus 71 antagonizes the inhibition of the host intrinsic antiviral factor A3G. Nucleic Acids Res. 2018;46:11514–27. https://doi.org/10.1093/nar/gky840CrossRefPubMedPubMedCentral

Li LF, Yu J, Li Y, et al. Guanylate-binding protein 1, an Interferon-Induced GTPase, exerts an antiviral activity against Classical Swine Fever Virus depending on its GTPase activity. J Virol. 2016;90:4412–26. https://doi.org/10.1128/JVI.02718-15CrossRefPubMedPubMedCentral

10.

Uno NRoss. T M dengue virus and the host innate immune response. Emerg Microbes Infect. 2018;7:167. https://doi.org/10.1038/s41426-018-0168-0

11.

Chen WJ, Xiong L, Yang L, et al. Long non-coding RNA LINC01783 promotes the progression of Cervical Cancer by sponging miR-199b-5p to Mediate GBP1 expression. Cancer Manag Res. 2020;12:363–73. https://doi.org/10.2147/CMAR.S230171CrossRefPubMedPubMedCentral

12.

Rameix-Welti MA, Le Goffic R, Herve PL, et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun. 2014;5:5104. https://doi.org/10.1038/ncomms6104CrossRefPubMed

13.

Zhang J, Yu X, Guo Y, et al. HPV16 E6 promoting cervical cancer progression through down-regulation of miR-320a to increase TOP2A expression. Cancer Med. 2024. https://doi.org/10.1002/cam4.6875CrossRefPubMedPubMedCentral

14.

Odetto D, Perrotta M, Saadi JM, et al. Infection versus cancer: management of actinomyces mimicking cervical cancer or ovarian cancer. Int J Gynecol Cancer. 2020;30:1638–43. https://doi.org/10.1136/ijgc-2020-001800CrossRefPubMedPubMedCentral

15.

Bogani G, V D I D, Sopracordevole F, et al. Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser conization: a 5-year follow-up study. Gynecol Oncol. 2020;159:636–41. https://doi.org/10.1016/j.ygyno.2020.08.025CrossRefPubMed

16.

Du H, Luo H, Wang C, et al. The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features. J Clin Epidemiol. 2021;139:319–29. https://doi.org/10.1016/j.jclinepi.2021.06.009CrossRefPubMed

17.

Habiger C, Jager G, Walter M, et al. Interferon Kappa inhibits human papillomavirus 31 transcription by inducing Sp100 proteins. J Virol. 2016;90:694–704. https://doi.org/10.1128/JVI.02137-15CrossRefPubMed

18.

Huang X, Huo L, Xiao B, et al. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. Cell Death Differ. 2024;31:78–89. https://doi.org/10.1038/s41418-023-01242-wCrossRefPubMed

19.

Hong SLaimins LA. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog. 2013;9:e1003295. https://doi.org/10.1371/journal.ppat.1003295CrossRef

20.

Miyauchi S, Kim SS, Jones RN, et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 2023;42:112508. https://doi.org/10.1016/j.celrep.2023.112508CrossRefPubMedPubMedCentral

21.

Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011;85:11372–80. https://doi.org/10.1128/JVI.05279-11CrossRefPubMedPubMedCentral

22.

Castro-Munoz LJ, Manzo-Merino J, Munoz-Bello JO, et al. The human papillomavirus (HPV) E1 protein regulates the expression of cellular genes involved in immune response. Sci Rep. 2019;9:13620. https://doi.org/10.1038/s41598-019-49886-4CrossRefPubMedPubMedCentral

Title: Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18
Authors: Min Xu
Miao-Chun Lin
Zhao-Hui Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Human Papillomavirus
Interferon
Cervical Cancer
Cervical Cancer
Published in: BMC Women's Health / Issue 1/2024
Electronic ISSN: 1472-6874
DOI: https://doi.org/10.1186/s12905-024-03057-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Sexuality and self-concept of morbidly obese women who are sexually attracted to men after bariatric surgery: a phenomenological study

Factors associated with antenatal depression among women attending antenatal care at Mubende Regional Referral Hospital: a cross-sectional study

COVID 19 vaccination as a trigger of acute genital ulcers in an immunocompromised adolescent—case study and literature review

Prevalence and associated factors of sexual dysfunction in female hemodialysis patients: first report from Somalia

Effect of diminished ovarian reserve on the outcome of fresh embryo transfer in IVF/ICSI cycles among young women: A retrospective cohort study

Exploring mental health problems and support needs among pregnant and parenting teenagers in rural areas Of Limpopo, South Africa